The therapeutic effect can be enhanced and broadened by combining tankyrase inhibition (TNKSi) with inhibitors of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), epidermal growth factor receptor, or mitogen-activated protein kinase against colorectal cancer xenografts (Schoumacher et al., 2014; Solberg et al., 2018). The gene discussed is TNKS; the disease is colorectal cancer.